Multiple sclerosis (MS) is defined as autoimmune and demyelinating condition of the central nervous system (CNS). Thus, inflammation, the main manifestation of innate and acquired immunity, is woven into the very fabric of MS. Inflammatory insult is, by definition, the first presentation of bout-onset MS. The more permanent sequalae of autoimmune inflammation of the CNS -such as brain atrophy or accrual of irreversible neurological disability -typically follow with a lag. 1 Immunosuppression and immunomodulation represent the standard approach to the management of MS. The repertoire of MS therapies has expanded dramatically. Patients and their neurologists may now choose among agents that modulate the numbers and the migration of T and B lymphocytes, modify the activity of anti-inflammatory T H lymphocytes or instigate broad immunosuppression. Set aside remyelinating treatment strategies, the development of which is underway, the common denominator of the currently available MS therapies is their effect on different steps in the immune cascade.
The success of immunotherapies in suppressing episodic inflammatory activity in relapsing MS forms is well established. This has been quantified as up to 94% reduction in the incidence of new or enhancing cerebral lesions and 68% reduction in the incidence of relapses. 2 In many randomised trials, the suppression of bout inflammatory activity translated into prevention of disability accrual over the short term.
There are a number of examples that suggest that the magnitude of the effect of highly potent immunotherapies is conditional on the studied cohorts' underlying inflammatory activity. For instance, the difference between alemtuzumab and interferon β-1a was more pronounced in the CARE-MS2 than the CARE-MS1 trial, where the former cohort had a relatively higher pretreatment relapse activity than the latter. 3, 4 Furthermore, in large observational studies, the effect of natalizumab on relapse frequency and improvement of disability was superior to fingolimod in cohorts with high level of disease activity. 5 One may argue that the accumulation of disability in primary progressive MS is disproportionate to the amount of CNS inflammation. However, inflammation in progressive MS forms is qualitatively different to relapsing-remitting MS. Compartmentalised inflammation in the form of leptomeningeal follicles and infiltration with lymphocytes and macrophages is a characteristic feature of progressive MS. 6 The fact that B cell-depleting therapies mitigate disability accrual in primary progressive MS provides an indirect evidence for implication of acquired immunity in progression of disability. 7 Moreover, subgroup analyses of the OLYMPUS and the ORATORIO trials suggested that patients with more prominent inflammatory activity prior to treatment derive more benefit from therapeutic B cell depletion. 7, 8 Previous studies using the Rennes cohort examined the mean time needed to progress from EDSS 3 to 6 in groups stratified by the time to reach EDSS 3, while excluding patients who did not reach EDSS step 6. 9 In the MSBase registry, we studied the variability of disability trajectories before and after these milestones (EDSS 3, 4 and 6), inclusive of patients who did not reach the next disability milestone. Contrary to the previous belief, we showed that disability trajectories in moderately advanced and advanced disease are widely variable ( Figure 1 ). 10 MS is indeed an amnesic condition, in which the future disability trajectory is only loosely associated with its previous trajectory. 11 Slopes of individual disability trajectories after patients reached the EDSS scores of 3, 4 or 6 are far from uniform. In fact, they are determined by the number of relapses that these patients continue to experience after the respective EDSS milestones. More importantly, disability accrual is mitigated in patients with greater exposure to potent immunotherapies after they have reached EDSS steps 3, 4 and 6. This observation not only shows that disability trajectories do not converge into one after patients have 
Controversies in Multiple Sclerosis
reached certain stage of their disease, but also that the rate of their progression remains modifiable, as long as their disease shows clinical signs of episodic inflammation.
However, the above studies in moderately advanced MS did not directly examine progressive MS phenotypes. In a recent study among 1419 patients from the MSBase registry, we assessed the impact of relapses on disability progression in patients with primary progressive MS. Contrary to our expectation, the study showed that patients with relapses superseded on primary progressive disease course (previously termed progressive-relapsing MS, now classified as active primary progressive MS 12 ) experience slower progression of disability than those without relapses. While it is surprising that relapses may serve as a positive prognostic marker, we also showed that, in the context of progressive disease, they represent a therapeutic target. Sustained immunotherapy is associated with slower progression of disability in patients with progressive disease with relapses. 13 Interestingly, we did not observe any benefit of sustained immunotherapy in patients with primary progressive MS who never experienced a relapse.
Another study among 496 patients with secondary progressive disease reported inconclusive results, when it found an association between superimposed relapses and the rate of progression from EDSS 4 to 7 but not EDSS 4 to 6. 14 On the other hand, a study among 529 patients suggested that relapses have a little impact on the hazard of reaching EDSS step 6. 15 While episodic inflammatory activity, whether subclinical or clinically manifest, may fuel more progressive changes in disability over the long term, prognostically, progression of disability and incidence of relapses represent two orthogonal dimensions of disease phenotype. The importance of this seemingly academic concept transpires into the conclusion that a relapse (or, more generally, an episode of inflammation) represents a target treatable with the currently available immunotherapies. As a consequence, progression and episodic inflammation represent two quantitative traits and any individual MS phenotype is a mix of the two components. Such view is supported by the most recent phenotypic classification of MS. 12 The emerging evidence summarised above means good news for patients. It suggests that anyone who experiences relapses may benefit from immunotherapy, regardless of whether their relapses occur in the context of more or less progressive MS course.
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https://orcid.org/0000-0003-37 78-1376 Figure 1 . Disability progression rates in 169 patients with relapsing multiple sclerosis who reached EDSS steps 3 and 6 confirmed over 6 months. Blue lines indicate the rates of transition between EDSS steps 0, 3 and 6, stratified into quintiles (both before and after EDSS 3). Marked variability in disability progression rates is apparent before and after EDSS 3 (based on the data presented in Lizak et al. 10 ). 
Where there is inflammation, treatment may reduce disability progression -No Gilles Edan and Sandra Vukusic
The respective weight of and the interplay between inflammatory and neurodegenerative components are highly variable in multiple sclerosis (MS), depending of age, disease duration, mainly of the clinical phase of the disease, relapsing-remitting, or progressive. As a consequence, the reduction of inflammation with disease modifying drugs (DMD) might have a highly variable impact on disability worsening, depending of the timing of their use, much better documented in the early phase of the disease, controversial at more advanced stages.
Natural history studies provided converging arguments that suggest relapses may not be a so important player in accumulation of disability in the long-term. In the early 2000s, the analysis of the Lyon EDMUS cohort 1 showed that once a clinical threshold of irreversible disability has been reached, the subsequent progression of disability was not affected by relapses, either those that occur before the onset of the progressive phase or those superimposed during this phase. Furthermore, clinical variables that were assessable early in the disease, including the number of relapses in the first 5 years, were predictors of the time from disease onset to the onset of irreversible disability, but not of the later stages. 2 Those initial results are in line with the findings of the London Ontario group, 3 showing that the progressive course of the disease was independent of the presence of no, one, or several relapses before onset of progression. In addition, the number of relapses experienced during the late relapsing-remitting phase (from year 3 to SPMS onset) did not show any deleterious effect on the key outcomes of secondary progression or on time to DSS 6, 8 or 10, highlighting two distinct disease phases related to disability worsening but separated by a watershed within the RR phase. 4 Similarly, in the Rennes EDMUS cohort, 5 the time from clinical onset to DSS3 was found to be clearly independent of the time from DSS3 to DSS6, and in relapsing onset MS, residual deficit after the first relapse and relapses during the first 2 years of MS were found to be independent predictors of disability progression during the early
